Next Article in Journal
Direct Alcohol Biomarkers Prediction Capacity on Relapse and Mortality in Liver Transplantation Candidates: A Follow-Up Study
Next Article in Special Issue
Effect of Remdesivir on COVID-19 PCR Positivity and Cycle Threshold in Kidney Transplant Recipients
Previous Article in Journal
Novel Kidney Auto Transplantation Technique for Ischemia-Reperfusion Studies
Previous Article in Special Issue
Presentation of SARS-CoV-2 in a Pediatric Heart Transplant Recipient with Multiple Underlying Comorbidities
Case Report

Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19

1
Division of Pulmonology, University Hospital Zurich, CH 8091 Zurich, Switzerland
2
Faculty of Medicine, University of Zurich, CH 8091 Zurich, Switzerland
3
Division of Internal Medicine, University Hospital Zurich, CH 8091 Zurich, Switzerland
4
Department of Thoracic Surgery, University Hospital Zurich, CH 8091 Zurich, Switzerland
*
Author to whom correspondence should be addressed.
Academic Editor: Brian C. Keller
Transplantology 2021, 2(2), 229-245; https://doi.org/10.3390/transplantology2020022
Received: 19 April 2021 / Revised: 3 June 2021 / Accepted: 4 June 2021 / Published: 15 June 2021
(This article belongs to the Special Issue Solid Organ Transplantation in the Era of COVID-19)
We report clinical features, treatments and outcomes in 18 lung transplant recipients with laboratory confirmed SARS-CoV-2 infection. We performed a single center, retrospective case series study of lung transplant recipients, who tested positive for SARS-CoV-2 between 1 February 2020 and 1 March 2021. Clinical, laboratory and radiology findingswere obtained. Treatment regimens and patient outcome data were obtained by reviewing the electronic medical record. Mean age was 49.9 (22–68) years, and twelve (67%) patients were male. The most common symptoms were fever (n = 9, 50%), nausea/vomiting (n = 7, 39%), cough (n = 6, 33%), dyspnea (n = 6, 33%) and fatigue (n = 6, 33%). Headache was reported by five patients (28%). The most notable laboratory findings were elevated levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH). Computed Tomography (CT) of the chest was performed in all hospitalized patients (n = 11, 7%), and showed ground-glass opacities (GGO) in 11 patients (100%), of whom nine (82%) had GGO combined with pulmonary consolidations. Six (33%) patients received remdesivir, five (28%) intravenous dexamethasone either alone or in combination with remdesivir, and 15 (83%) were treated with broad spectrum antibiotics including co-amoxicillin, tazobactam-piperacillin and meropenem. Four (22%) patients were transferred to the intensive care unit, two patients (11%) required invasive mechanical ventilation who could not be successfully extubated and died. Eighty-nine percent of our patients survived COVID-19 and were cured. Two patients with severe COVID-19 did not survive. View Full-Text
Keywords: SARS-CoV-2; viral infection; hyperinflammation; cytokine storm syndrome; dexamethasone; remdesivir; hemodialysis SARS-CoV-2; viral infection; hyperinflammation; cytokine storm syndrome; dexamethasone; remdesivir; hemodialysis
Show Figures

Figure 1

MDPI and ACS Style

Hage, R.; Steinack, C.; Gautschi, F.; Pfister, S.; Inci, I.; Schuurmans, M.M. Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19. Transplantology 2021, 2, 229-245. https://doi.org/10.3390/transplantology2020022

AMA Style

Hage R, Steinack C, Gautschi F, Pfister S, Inci I, Schuurmans MM. Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19. Transplantology. 2021; 2(2):229-245. https://doi.org/10.3390/transplantology2020022

Chicago/Turabian Style

Hage, René, Carolin Steinack, Fiorenza Gautschi, Susan Pfister, Ilhan Inci, and Macé M. Schuurmans 2021. "Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19" Transplantology 2, no. 2: 229-245. https://doi.org/10.3390/transplantology2020022

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop